Remove Engineering Remove Immune Response Remove Licensing
article thumbnail

2025 Merkin Prize in Biomedical Technology awarded to pioneers of CAR T-cell therapy

Broad Institute

He showed that these synthetic CAR T cells could launch an immune response when they encountered the corresponding tumor protein, called CD19. Our initial work with engineered T cells in HIV patients revealed that these cells could persist in the body far longer than anticipated, said June, who is the Richard W.

Therapies 119
article thumbnail

FDA takes major step to ease access to CAR-T therapy

BioPharma Drive: Drug Pricing

Published June 27, 2025 Ned Pagliarulo Lead Editor post share post print email license Bristol Myers Squibb sells two CAR-T cell therapies for cancer. These medicines are made from a patient’s own immune cells, extracted from the body and engineered in a lab to hunt down specific proteins found on the surface of malignant clones.

Therapies 178
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

ImaginAb Announces License and Supply Agreement with Pfizer for CD8 ImmunoPET Technology

The Pharma Data

a leading global provider of immuno-oncology imaging agents, today announced it has signed a new multi-year, non-exclusive license with Pfizer Inc. ImaginAb will receive license fees and payments for manufacturing and other support. LOS ANGELES , Jan. 7, 2021 /PRNewswire/ — ImaginAb Inc. , No other terms were disclosed.

article thumbnail

Merck Strikes $1B+ Deal to Leverage Janux’s T Cell Engager Program Against Cancer

The Pharma Data

Merck will select cancer targets and harness Janux’s proprietary Tumor Activated T Cell Engager (TRACTr) technology to engineer novel, T cell engager drug candidates. Janux technology can be applied to immunotherapies that target all three stages of an anti-tumor immune response.

article thumbnail

COVID-19 nasal vaccine candidate effective at preventing disease transmission

The Pharma Data

Anderson Professor of Chemical and Biomolecular Engineering, and his colleagues, are reporting in iScience the event of an intranasal subunit vaccine that gives durable local immunity against inhaled pathogens. A fundamental limitation of intramuscular vaccines is that they’re not designed to elicit mucosal immunity.

Vaccine 52
article thumbnail

Gamma delta T cells: a rising star in cancer therapy

Drug Target Review

These include engineering the cells to express cytokines that promote their maturation and/or differentiation, and engineering drug-resistant γδ T cells that can be combined with chemotherapies, which stress cancer cells but would otherwise also deplete the T-cell population. References Fichtner A, Ravens S, Prinz I.

Therapies 105
article thumbnail

Taconic Biosciences Expands Immuno-oncology Animal Model PortfolioCritical Jh Syngeneic Tumor Model Host Now Available on a B6 Background

The Pharma Data

One consideration in using syngeneic models is that some drug candidates can cause a negative immune response not seen in humans. Taconic Biosciences is a fully-licensed, global leader in genetically engineered rodent models and services.